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Abstract
Background: Moyamoya disease is an idiopathic vascular disorder of intracranial arteries. Its susceptibility locus has been
mapped to 17q25.3 in Japanese families, but the susceptibility gene is unknown.
Methodology/Principal Findings: Genome-wide linkage analysis in eight three-generation families with moyamoya disease
revealed linkage to 17q25.3 (P,10
-4). Fine mapping demonstrated a 1.5-Mb disease locus bounded by D17S1806 and
rs2280147. We conducted exome analysis of the eight index cases in these families, with results filtered through Ng criteria.
There was a variant of p.N321S in PCMTD1 and p.R4810K in RNF213 in the 1.5-Mb locus of the eight index cases. The p.N321S
variant in PCMTD1 could not be confirmed by the Sanger method. Sequencing RNF213 in 42 index cases confirmed
p.R4810K and revealed it to be the only unregistered variant. Genotyping 39 SNPs around RNF213 revealed a founder
haplotype transmitted in 42 families. Sequencing the 260-kb region covering the founder haplotype in one index case did
not show any coding variants except p.R4810K. A case-control study demonstrated strong association of p.R4810K with
moyamoya disease in East Asian populations (251 cases and 707 controls) with an odds ratio of 111.8 (P=10
2119).
Sequencing of RNF213 in East Asian cases revealed additional novel variants: p.D4863N, p.E4950D, p.A5021V, p.D5160E, and
p.E5176G. Among Caucasian cases, variants p.N3962D, p.D4013N, p.R4062Q and p.P4608S were identified. RNF213 encodes
a 591-kDa cytosolic protein that possesses two functional domains: a Walker motif and a RING finger domain. These exhibit
ATPase and ubiquitin ligase activities. Although the mutant alleles (p.R4810K or p.D4013N in the RING domain) did not
affect transcription levels or ubiquitination activity, knockdown of RNF213 in zebrafish caused irregular wall formation in
trunk arteries and abnormal sprouting vessels.
Conclusions/Significance: We provide evidence suggesting, for the first time, the involvement of RNF213 in genetic
susceptibility to moyamoya disease.
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Introduction
Moyamoya disease is an idiopathic disorder characterized by
occlusive lesions in the supraclinoid internal carotid artery and its
main branches in the circle of Willis. To compensate for the blood
flow around the occlusive region, a fine vascular network develops
that resembles ‘‘puffs of smoke’’ (Figure 1A) [1]. The unique
appearance of moyamoya vessels described by Suzuki and Takaku
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[MIM 607151] (Online Mendelian Inheritance in Man in
Appendix S1). Moyamoya disease occurs worldwide [3], but its
prevalence is highest in East Asian countries, including Japan (1 in
10,000), Korea and China [4], [5]. It is known to cause stroke in
neonates and children, and therefore pathological clues for early
diagnosis and novel therapeutic approaches are needed [6].
The occlusive lesions are caused by excessive proliferation of
smooth muscle cells (SMCs), which specifically occurs in arteries in
the skull with compensatory bypass vessels (Figure 1B) [7]. These
occlusive lesions are similar to those of atherosclerosis in that both
types of lesion exhibit endothelial injury, SMC proliferation and
intimal hyperplasia. However, there are major differences between
the two types: in moyamoya vessels, infiltrating cellular compo-
nents such as macrophages and lipid deposits are not observed [8].
A recent study revealed that accelerated vascular remodeling
might underlie the pathological consequences of moyamoya
disease [9]. Clinical investigations have revealed elevated levels
of certain growth factors or cytokines in the cerebrospinal fluid,
serum or blood vessels of patients with moyamoya disease [10]–
[15]. These factors are assumed to be associated with vascular
remodeling.
Epidemiological studies have revealed several risk factors
associated with moyamoya disease, including Asian ethnicity,
female gender and a family history of the disease [4]. Given that
15% of moyamoya patients have a family history of the disease,
genetic factors are suspected to underlie its pathogenesis.
Several studies have explored genetic factors and revealed four
loci associated with moyamoya disease: 3p24–p26 [16], 6q25 [17],
8q23 [18] and 17q25 [19]. The locus on 17q25, first mapped by
Figure 1. Clinical features of moyamoya disease. (A) An anterior-posterior and lateral views of left internal carotid angiography in a 9-year-old
child with moyamoya disease (right) and an 8-year-old control child (left). An occlusion with moyamoya vessels can be seen around the terminal
portion of the internal carotid artery and proximal portions of the anterior cerebral artery and middle cerebral artery in the affected child. (B) Intimal
hyperplasia in the middle cerebral artery from an autopsy of a 69-year-old case. Intimal hyperplasia (red arrowhead), atrophic media (red arrow) and
winding internal elastic lamina (black arrow) can be seen with Elastica Masson staining, 6200.
doi:10.1371/journal.pone.0022542.g001
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previous study, a strong association of a variant (ss161110142) was
demonstrated in East Asian patients, suggesting a possible East
Asian founder haplotype for moyamoya disease [21]. The major
aim of the present study was to identify the causative gene for
moyamoya disease. In the present study, we conducted exome
analysis and identified ring finger protein 213 (RNF213; DDBJ/
EMBL/GenBank accession number AB537889) [National Center
for Biotechnology Information (NCBI) in Appendix S1] as a
susceptibility gene. In this study, we cloned RNF213 and
determined its open reading frame (ORF). Compared with the
previously registered RNF213 sequence [NM_020914.4] (NCBI in
Appendix S1), our RNF213 clone possesses a 2,500-bp longer 39
untranslated region (UTR) and lacks exon 4. Since we found that
AB537889 seems to be the major transcript of RNF213, the
descriptions of RNF213 in this paper are primarily based on the
newly determined ORF unless otherwise stated.
Methods
Ethical statement
Ethical approval for this study was given by the Institutional
Review Board and Ethics Committee of Kyoto University School
of Medicine, Kyoto University, Japan (approval number: G140;
approval date: 10/18/2004); by the Ethics Committee of the
medical faculty of the University of Tu ¨bingen (Ethik-Kommission
der Medizinischen Fakulta ¨t des Universita ¨tsklinikums Tu ¨bingen;
permit number: 273/2009BO1; approval date: 1/1/2009); by
Seoul National University Hospital Institutional Review Board
(approval number: H0507-509-153; approval date 8/24/2005); by
the Medical Ethics Committee of Beijing Children’s Hospital
Institutional Review Board, Capital Medical University, China
(approval number: 2005-31; approval date: 3/15/2005); and by
the Ethics Committee of University Hospital and the Faculty of
Medicine of Palacky University in Olomouc (reference number:
62/10; approval date: 8/18/2008). Participants were recruited in
these institutes. All subjects gave written informed consent, or for
those considered too young to consent, informed consent was
given by their parent or guardian.
Subjects
Diagnostic criteria were based on the Japanese Research
Committee on moyamoya disease of the Ministry of Health,
Welfare and Labour, Japan (RCMJ) criteria [22]. Information on
family histories, gender, age of onset, onset of symptoms and
unilateral or bilateral moyamoya disease was obtained either by
interview or by clinical chart review, as previously reported [21],
[23].
We recruited East Asian cases (Japanese, Korean and Chinese),
as described previously [21]. The participants comprised 41
Japanese families and one Korean family (Figure S1 and Table
S1), 209 unrelated cases (120 Japanese, 37 Korean and 52
Chinese). We recruited 757 unrelated controls: 384 Japanese, 223
Korean and 100 Chinese (Table S2) and an additional 50 Chinese
adult females [Mean age at participation (years 6 SD):
38.4610.5].
We also recruited a Caucasian family of Czech ethnicity (Figure
S2A) and 7 unrelated Czech and 42 German cases with
moyamoya disease at the University of Tubingen (Germany),
and Palacky University and University Hospital (Olomouc, Czech
Republic). The mean age (years 6 SD) at diagnosis was
30.4614.7, and the sex ratio of males:females was 16:33. The
284 Caucasian controls were recruited from Palacky University
and University Hospital (n=120), the University of Tubingen
(n=164) and another 100 Caucasian control samples (the Coriell
Caucasian Panel) were bought from the Coriell Institute. The
mean age (years 6 SD) was 43.9617.9 and the sex ratio of
males:females was 176:208. No magnetic resonance imaging
screening of the controls was conducted.
Linkage, haplotype and segregation analyses
We conducted a parametric genome-wide linkage analysis using
GENEHUNTER [24] (GENEHUNTER Ver2.1_r6: Appendix
S1) in the eight largest three-generation families (peds. 2, 10, 14,
15, 17–20) (Figure 2) with an ABI Prism Linkage Mapping Set
(Version 2; Applied Biosystems) with 382 markers, 10 cM apart,
for 22 autosomes, and fine-mapping markers designed according
to information from the uniSTS reference physical map (http://
www.ncbi.nlm.nih.gov/genome/sts/). Unaffected members were
treated as ‘‘phenotype unknown’’ because of the incomplete and
age-dependent penetrance of moyamoya disease [20]. We
considered obligate carriers and subjects with unilateral occlusion
or stenosis around the circle of Willis as affected, as previously
reported [20]. The disease allele frequency was set at 0.00002 and
a phenocopy frequency of 0.000001 was assumed, as previously
reported [20]. Population allele frequencies were assigned equal
portions for individual alleles. We performed multipoint analyses
for autosomes and obtained logarithm of the odds (LOD) scores.
Haplotypes were constructed with GENEHUNTER and segrega-
tion was investigated using the constructed haplotypes.
To calculate the statistical significance level of the linkage to
17q25.3 in the eight families, we applied a bootstrap method using
simulation, as previously reported [25]. We simulated recombi-
nation events for 22 chromosomes in these eight families,
calculated multipoint LOD scores by GENEHUNTER and
obtained the maximum total LOD scores in each trial. The
simulation was run 10,000 times.
Exome analysis
We conducted exome analysis on one index case from each of
the eight families (peds. 2, 10, 14, 15, 17–20) (Figure 2), who were
diagnosed with moyamoya disease based on RCMJ criteria. We
targeted all protein-coding regions as defined by RefSeq37
(RefSeq in Appendix S1). Approximately 210,121 coding exons
in the 20,794 target genes from 10mg of genomic DNA from each
case were captured using an Agilent SureSelect Human All Exon
kit, following the manufacturer’s protocols. Briefly, DNA was
sheared by acoustic fragmentation (Covaris) and purified using a
QIAquick PCR Purification kit (Qiagen). The quality of the
fragmentation and purification was assessed with an Agilent 2100
Bioanalyzer. The fragment ends were repaired and adaptors were
ligated to them (NEBNext DNA sample prep; New England
Biolabs). The resulting DNA library was purified using a
QIAquick PCR Purification kit, amplified by PCR and captured
by hybridization to the biotinylated RNA library ‘‘baits’’ (Agilent).
The whole-exome DNA library was sequenced on an Illumina
Genome Analyzer IIx in 76-bp paired-end reads using two
channels. Sequence reads were mapped to the reference human
genome (Ghr37/hg19) (NCBI and UCSC Genome Browser in
Appendix S1) using ELANDv2 software (Illumina). Variant
detection was performed with CASAVA software (version 1.7;
Illumina). Sequence calls were filtered to include only those with
.8 coverage, .30 consensus quality and .20 mapping quality.
Candidate variants were filtered by SAMtools (Appendix S1). For
comparison, we used an exome database of five Japanese controls,
who do not have histories of stroke, for which the analysis was
conducted by the same protocol and experimental procedures.
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method
Genomic DNA was extracted from blood samples with a
QIAamp DNA Blood Mini kit (Qiagen). The whole RNF213 gene
was sequenced, including the 59 promoter region at least 2 kb
upstream of the first exon, 50–300 bp of each intron upstream and
downstream of each exon, all the exons and throughout the 39
UTR. Target sequences, including the skipped exon 4 were based
on the open reading frame of NM_020914.4. Sequencing exon 8
of PCTDM1 was conducted to confirm the exome result.
Sequencing primers were commercially synthesized (PROLIGO
Primers & Probes) (Table S3) (Appendix S1). The PCR products
were separated on an ABI Prism 3130 Avant DNA sequencer
(Applied Biosystems, Tokyo, Japan).
Deep sequencing of introns and intergenic regions of
RNF213
To search for a hidden causative variant, we sequenced the
entire 260-kb genomic region from the 59 end of SLC26A11 (bp
78194200) to the 59 end of NPTX1 (bp 78450404) (NCBI in
Appendix S1) in the index case of pedigree 11, who was
homozygous at 17q25.3 because of parental consanguineous
marriage, using two bacterial artificial chromosome (BAC) clones
(bp 78194200–78238718 and bp 78345170–78450404) (Table S4)
or by direct sequencing. The entire RNF213 gene including
promoters, 59UTR, introns, exons and 39UTR was sequenced in a
control sample in the same way as for the index case of pedigree
11. Since we failed to sequence intron 15 of RNF213, we used
Southern blotting to detect a possible expansion. Details of the
BAC cloning and Southern blotting are described in the Text S1.
The primer sequences are listed in Table S3.
Genotyping of five rare variants (ss179362671,
ss179362673 (p.R4810K), ss179362674, ss179362675
ss161110142) and 34 other single nucleotide
polymorphisms (SNPs)
Typingof the fiverare variants and 34SNPs was conductedusing
Taqman probes (TaqMan SNP Genotyping Assays; Applied
Biosystems) using a 7300/7500 Real-Time PCR System (Applied
Biosystems) (dbSNP 131 and Hapmap database in Appendix S1).
The transmitted haplotypes in 42 families were constructed using
GENEHUNTER. Details of the 39 SNPs are described in the Text
S1. The allele frequencies were determined in Japanese controls.
Copy number variations (CNVs)
We performed genotyping with Affymetrix 500K arrays
(GeneChipH Mapping 250/500 K; Affymetrix, Inc.) according to
the manufacturer’s protocol. Genomic DNA samples donated by
the index cases of pedigrees 5, 11 and 18 and the control spouse of
2 of pedigree 18 were analyzed. The genome-wide call rates were
.95% for all the genomic DNAs. CNVs were identified from the
intensities using the Affymetrix GeneChipH Chromosome Copy
Number Analysis Tool software V.4.01. CNVs were observed
using CNAG viewer (Version 2.0; Takara).
Association study with p.R4810K (ss179362673)
Association studies were conducted between 161 Japanese cases
(41 index cases from Japanese families and unrelated 120 cases)
and 384 Japanese controls, between 38 Korean cases (the index
case from a Korean family and 37 cases) and 223 Korean controls
and between 52 Chinese cases and 100 Chinese controls (Tables
S1 and S2). Cases were exclusively diagnosed as moyamoya by
RCMJ criteria.
The association was investigated using SNP & Variation Suite
V7 (Golden Helix, Inc. in Appendix S1). Allelic, additive,
dominant and recessive models were tested. Population-attribut-
able risk (PAR) was defined as PAR =100*(K–y)/K, where K is
the population prevalence and y is the phenocopy proportion that
was estimated from the number of cases with the risk allele [21].
Screening of RNF213 polymorphisms in controls
Five RNF213 variants, p.D4863N, p.E4950D, p.A5021V,
p.D5160E and p.E5176G were screened in 757 East Asian
controls: 384 Japanese, 223 Korean, and 150 Chinese. Four
variants, p.N3962D, p.D4013N, p.R4062Q and p.P4608S, were
screened in 384 Caucasian controls: 120 Czech, 164 German, and
100 Caucasian. The screening methods are described in the Text
S1 and in Table S5.
Immortalized cell lines, cell culture and transient
transfection
Lymphoblastoid cell lines (LCLs) were isolated and immortal-
ized with Epstein-Barr virus for five unrelated controls (three
individuals, the spouse of individual 2 in pedigree 18 and the
spouse of individual 12 in pedigree 17) and six cases (individuals 2
and 22 in pedigree 18, individual 11 in pedigree 11 and individuals
12, 121 and 122 in pedigree 17). HeLa cells and human
embryonic kidney (HEK) 293 cells were cultured in Dulbecco’s
modified Eagle’s medium (Invitrogen) supplemented with 10%
fetal bovine serum. Human umbilical vein endothelial cells
(HUVECs) and coronary artery smooth muscle cells (CASMCs)
were grown in EBM-2 and SmBM-2 (Lonza), respectively.
Expression plasmids were transfected into cells using Lipofecta-
mine LTX (Invitrogen) in accordance with the manufacturer’s
instructions.
Cloning of RNF213 and construction of an expression
vector
We cloned RNF213 and constructed wild-type and various
mutants of the RNF213 expression vector as described in the Text
S1. Nucleotide sequence data reported are available in the DDBJ/
EMBL/GenBank databases under the accession number AB537889
(NCBI in Appendix S1).
Detection of splicing products of RNF213 cDNA or
FLJ35220 cDNA and real-time quantitative PCR
A Human Total RNA Master Panel II (Clontech Inc) and total
RNA from the Artery (BioChain) were reverse-transcribed into
cDNA using the High Capacity cDNA Reverse Transcription kit
(Applied Biosystems). We tested whether RNF213 cDNA skipped
exon 4 of RNF213 by molecular sizing and direct sequencing of
cDNA isolated from the RNA of the above human tissues,
HUVECs, and LCLs isolated from the five controls and six cases.
The PCR primers were designed to cover exons 3–5 as described
in the Text S1. We also tested whether or not FLJ35220 cDNA
skipped exon 11 of FLJ35220 due to G.A substitution in the
Figure 2. The eight three-generation families and haplotype construction with fine markers. For familial index cases in the eight
pedigrees, the haplotypes are indicated by the boxes constructed in GENEHUNTER [24]. The smallest disease haplotype spanning from D17S1806 to
rs2280147 was estimated by the region common to both 1411 in the pedigree 2 and 132 in pedigree 20.
doi:10.1371/journal.pone.0022542.g002
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four cases and three controls.
Quantitative PCR was performed using the THUNDERBIRD
SYBR qPCR mix (TOYOBO) and a 7300 Real Time PCR
System (Applied Biosystems). The primer sequences for RNF213
cDNA or FLJ35220 are described in the Text S1.
Northern blotting
Total RNA was isolated using a QIAamp RNA blood mini kit
(Qiagen Inc.). A human adult normal tissue mRNA northern blot I
(Biochain) was probed in accordance with the supplier’s
recommendations. The two probes [RNF213_1 (492 bp) and
RNF213_2 (591 bp)] have been described in the Text S1. The
mRNA levels were determined using an Image Analyzer FLA2000
(Fuji Film).
Rapid amplification of cDNA ends (RACE)
The 59 and 39 ends of the RNF213 cDNA were determined by
RACE using a GeneRacer kit (Invitrogen) according to the
manufacturer’s protocol. Details can be found in the Text S1.
Allele-specific mRNA expression assay
Polymorphisms of p.R4810K and a nearby SNP, p.H4557H, in
RNF213 cDNA were used as markers for the SNaPshot assay to
measure the expression of the two alleles. Primers for the
SNaPshot assay are shown in Table S6.
Western blotting
Cells were lysed in buffer containing 50 mM Tris-HCl pH 8.0,
1% NP-40 and 150 mM NaCl, or in CelLytic M (Sigma) containing
a protease inhibitor cocktail. Samples were subjected to immuno-
blotting using an anti-RNF213 antibody (MyBioSource), anti-HA
antibody (mouse 6E2; Cell Signaling Technology) or anti-Myc
antibody (mouse 9E10; Santa Cruz).
Immunostaining
The methodology used for immunostaining has been described
in detail in the Text S1.
Ubiquitin ligase assay
Plasmids, immunoprecipitation and the self-ubiquitination assay
have been described in a previous report [26]. Briefly, cells were
lysed in buffer containing 50 mM Tris-HCl pH 8.0, 1% NP-40
and 150 mM NaCl, then centrifuged at 13,000 6 g. The
supernatants were incubated with an anti-HA antibody, and
immune complexes were captured using protein G-Sepharose (GE
Healthcare). Immunoprecipitates were subjected to immunoblot
analysis using an anti-Myc antibody.
Protein preparation and ATPase assay
TheregioncontainingtheWalker motif(aminoacids2359–2613)
was subcloned into the bacterial expression vector pGEX5X-1. The
N-terminal glutathione S-transferase (GST)-tagged fragment was
first purified with GSH beads (GE Healthcare), then was purified
using a gel-filtration column (Superdex 200 prep grade; Amersham
Pharmacia) in conjunction with the AKTAexplorer system (GE
Healthcare). The ATPase assay was performed as described in
Text S1.
Effects of p.R4810K or p.D4013N on biochemical function
of RNF213
Nucleotide changes corresponding to p.R4810K and p.D4013N
were introduced into RNF213 using a site-directed mutagenesis kit
(Invitrogen). These mutants were transiently expressed in
HEK293 cells as described in the Text S1. Cells were then lysed
and subjected to the ubiquitin ligase assay as described above, or
subjected to subcellular fractionation as described in the Text S1.
To generate a RING finger-deleted mutant of RNF213,a n
exogenous EcoRI site was fused to the 39 terminus just before the
RING finger domain, then this site was ligated to an endogenous
EcoRI site located just after the RING finger, enabling the RING
finger domain to be skipped from the RNF213 cDNA.
Zebrafish model
The Zebrafish experiments were approved by the Osaka
University Animal Welfare committee (Osaka University, Japan;
approval ID 2197). Embryos and adult fish were raised and
maintained under standard laboratory conditions. For in vivo
experiments, Tg(fli-EGFP)y1 zebrafish [27] were purchased from
the Zebrafish International Resource Center. Knockdown of
RNF213-a and RNF213-b expression was achieved by injection of
a specific morpholino (MO; Gene Tools) into 1- to 8-cell stage
embryos, as described previously [28]. The methods are described
in detail in the Text S1.
Results
Linkage analysis and identification of the critical region
Linkage analysis for the eight largest families (Figure 2) revealed
a single peak at 17q25.3 with a multipoint LOD score of 8.46 at
D17S784 (Figure 3). The largest maximum multipoint LOD score
in the 10,000 simulations was 7.25 with a median of 3.56 and a
95% confidence interval between 2.16 and 5.48. Thus, linkage of
the eight families to 17q25.3 was highly statistically significant and
was unlikely false positive. To evaluate the effect of uncertainty
regarding the allele frequency of the disease gene, we conducted a
sensitivity analysis by changing the values to 0.000001, 0.001 or
0.01. The sensitivity analysis did not change the maximum
multipoint LOD score by more than 1%.
Fine mapping increased the LOD score slightly to 8.52 at
D17S784, and revealed several recombination events in the region
involving the two flanking markers D17S1806 and rs2280147
(Figure 2). Thus, the core of the locus was a 1.5-Mb region, which
harbored 21 genes from hCG 1776007 to RPL31P7 (Table S4).
Figure 3. Genome-wide linage analysis uniquely identified a
locus on 17q25.3 for the eight families. Genome wide linkage
analysis showed a highest LOD score (8.46) at D17S784 in the locus
17q25.3.
doi:10.1371/journal.pone.0022542.g003
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families (Figure 2).
Exome analysis
We generated approximately 154 million reads with an on
target rate of 59.1%. Twelve billion bases passed the quality
assessment and were aligned to the human reference sequence;
.98.1% of the bases mapped to the target, with a mean coverage
depth .116.8 in each index case. For coverage on the 1.5-Mb
region on 17q25.3, we generated approximately 97000 reads with
an on target rate of 52.5%. The mean coverage depth was 48.7
with 288 exons, assuring that all genes were adequately covered.
We applied Ng et al. ’s filtering algorithm [29], with some
modifications to make it less stringent because we anticipated
genetic heterogeneity and an uncharacterized gene. Additionally,
because a reported discordance of phenotype between identical
twins indicated a low penetrance [20], [21], we considered as
candidates both rare variants that are specific to moyamoya, and
more common variants that are more frequently observed in cases
than in controls.
We compared our missense (MS)/nonsense (NS)/splicing site
(SS)/insertion or deletion (Indel) variants in the eight index cases
against dbSNP 131 (Appendix S1) and the exome database of the
five Japanese controls, and removed the reported SNPs and SNPs
found in the five Japanese controls (Table 1).
The mean numbers of MS/NS/SS/Indel per cases were 6601
from the genome-wide analysis. We next examined the effects on
the size of the candidate gene list when analyzing the exomes of
the eight index cases in various combinations and examined the
potential consequences of genetic heterogeneity, such that only a
subset of the exomes of index cases was required to contain new
variants in a given gene for it to be considered as a candidate gene
(Table 1 and S7). In the second stage of the filtering in which we
assumed that any seven of the eight index cases shared the
causative gene (Table S7), the numbers of the candidate genes
were decreased to two. By filtering two variants in the two genes
emerged as candidates (Table 1 and Table S7). These two variants
were p.N321S in PCMTD1 (Chr8: NM_052937) and p.R4810K in
RNF213 (Chr17: NM_020914.4). PCMTD1 encodes the protein-L-
isoaspartate O-methyltransferase domain-containing protein
1(Genecard in Appendix S1) ; RNF213 encodes ring finger protein
213. We thus considered both PCMTD1 and RNF213 as candidate
genes.
Confirmation of the exome data by direct sequencing
and segregation analysis
In the next step, we conducted sequencing to confirm p.N321S
in PCMTD1 and sequenced the entire exons of RNF213 with an
ORF (NM_020914.4) in 42 index cases by the Sanger method
(Table S3). We could not confirm p.N321S in PCMTD1 in any of
the eight index cases by the Sanger method. Thus we discarded
PCMTD1. In contrast, we could confirm p.R4810K by the Sanger
method in 42 index cases but could not find any other unregistered
polymorphism in RNF213. We genotyped other family members
in the 42 families. As shown in Figure S1, p.R4810K was
completely segregated in 42 families: all the affected members by
RCMJ criteria had p.R4810K, although some carriers were not
affected with moyamoya disease, suggesting low penetrance.
Deep sequencing around RNF213
To avoid a possible pitfall of exome for searching variants in
introns or intergenic regions, we sequenced the entire 260-kb
genomic region (UCSC Genome Browser in Appendix S1) around
RNF213 from the 59 end of SLC26A11 to the 59 end of NPTX1 in
the index case of pedigree 11 using BAC clones or direct
sequencing. Sequencing the 2.7-kb intron 15 of RNF213 failed
because of the presence of repeats. Southern blotting of the eight
index cases and a control (the spouse of individual 2 in pedigree
18) confirmed the absence of insertions or deletions in this intron
(data not shown). However, sequencing of the 260-kb genomic
region revealed three additional unregistered variants in noncod-
ing regions: ss179362671 (T.C) in intron 15 of RNF213,
ss179362674 (G.A) in intron 11 of FLJ35220 and ss179362675
(C.T) at the 39 end of NPTX1, 1868 bp downstream from the
39UTR.
Exonic rare variants of RNF213 in Japanese controls
We then sequenced all the exons of RNF 213 in ten controls and
conducted deep sequencing of RNF213 for a Japanese control.
These results and five controls for exome analysis are shown in
Table S8. Additionally, 38 chromosomes inherited from parents in
38 index cases, which do not carry p.R4810K, can be identified to
Table 1. Numbers of variants identified based on filtering.
Index Case of the Family
Stage Criteria Ped 2 Ped 10 Ped 14 Ped 15 Ped 17 Ped 18 Ped 19 Ped 20 Any eight
1st Stage MS/NS/SS/Indel 6638 6741 6512 6668 6561 6361 6822 6507 1038
Not in dbSNP131 983 1036 963 966 953 1064 1019 934 75
2nd Stage Not in the five
Japanese controls*
583 590 565 611 594 534 624 605 2 : p.N321S in
PCMTD1 and
p.R4810K in RNF213
No of genes 377 379 364 372 375 354 380 385 2
I n t h e 1 7 q 2 5 . 31 1 1133 12 1
Genes No of genes RNF213
1
RNF213
1
RNF213
1
RNF213
1
RNF213
GAA
ENPP7
3
RNF213
ENPP7
SLC26A11
3
RNF213
1
RNF213
SLC26A11
2
RNF213
1
Rows show the effect of excluding from consideration of variants found in dbSNP131 and the five Japanese controls. Columns show MS/NS/SS/Indel variants that were
observed in each affected individual. The column 10 provided observation that shared by all affected index cases.
*Exome analysis were conducted using the same platform and same experimental conditions for five Japanese controls.
doi:10.1371/journal.pone.0022542.t001
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observed sample size of control chromosomes accounts for 70 (five
controls by exome, 10 controls by direct sequencing, one by deep
sequencing, and 38 chromosomes inherited from unaffected
parents of 38 index cases). Given that the statistical power should
be greater than 80%, rare exonic variants with minor allele
frequencies of as low as 2% could be detected in the sample size of
70. However, we could not find any unregistered rare variants on
control chromosomes.
Possible masked variants in the linkage disequilibrium
(LD) region with p.R4810K (ss179362673) and possible
CNVs in 17q25.3
Although p.R4810K seems to be a strong candidate for
causative variants of moyamoya disease, there also seem to be
other possibilities. One of these is the presence of masked variants
in the promoters, or intronic or intergenic regions of a bona fide
causal gene, which are in strong LD with p.R4810K.
We determined the minor allele frequencies for five unregistered
variants found in this study and a previous study [21] in Japanese
controls. The frequencies were 0.012 (p1=9/768) for ss179362671,
0.014 (p2=11/768) for ss179362673, 0.013 (p3=10/768) for
ss179362674, 0.022 (p4=17/768) for ss179362675 and 0.010
(p5=8/768) for ss161110142 in 384 Japanese controls, indicating
that theyareallrare variants.Wethen genotyped the 42families.As
shown in Figure 4, these four rare variants were transmitted en bloc
with p.R4810K. They comprised five subhaplotypes (Figure 5); and
p.R4810K was not transmitted alone in any of the families.
Haplotype 2, the most prevalent haplotype, was found in
34 of the 42 families. Because all five variants are rare, it is
unlikely that haplotype 2 has been formed by chance
(p=2
56p16p26p36p46p5=1.5610
28). Alternatively, a more
rational explanation is to assume that haplotype 2 is the founder
haplotype. Along this line, haplotypes 3–6 may be explained by
historical recombination events. Given historical recombinations,
the number of masked variants is very likely to be one and it
should be located in the core LD region between ss179362671 and
ss179362675 (Figure 5).
Further confirmation of the sequence homogeneities was
evaluated by genotyping of 34 additional markers. Transmissions
of the 39 SNPs covering SGSH to Raptor were investigated in the 42
families. The five haplotypes were further classified into subtypes
(Figure 5). The typing results confirmed the sequence homogeneity
in the core LD region (Figure 5). The genotyping of the SNPs in
the RNF213 regions were completely in accord with the
sequencing results in the 42 index cases. Thus, we concluded that
the core LD region has been very likely derived from the founder
haplotype.
Although we sequenced the coding and non-coding regions in
the index case of pedigree 11, we did not detect any unregistered
rare variants other than the five rare variants, supporting that
p.R4810K or G.A substitution in the intron 11 of FLJ35220 is a
susceptibility variant. In terms of G.A substitution in the intron
11 of FLJ35220, we have tested two possibilities, namely that the
substitution may induce aberrant splicing or change gene
expression levels. Either possibility was discarded (Figure S3).
We still tested another possibility. It can sometimes be difficult to
detect CNVs by direct sequencing. Therefore, we evaluated the
CNVs using a high-density microarray, with a theoretical
sensitivity estimated to be 41 kb [30]. However, we did not detect
any CNVs in the 17q25.3 region in the three index cases of
pedigrees 5, 11 and 18 and a control 2 in pedigree 18 (Figure S4).
Although we cannot theoretically discard the very rare
possibility of multiple masked variants having strong LD with
p.R4180K by various LD patterns specific to the individual
families, these data collectively indicate that it is not a surrogate
marker of possible masked variants of another gene. Therefore,
RNF213 is very likely to be a bona fide susceptibility gene for
moyamoya disease.
Association of p.R4810K with moyamoya disease in East
Asian patients
We next tested the association of RNF213 p.R4810K with
moyamoya disease in East Asian populations. Unrelated cases and
index cases were exclusively limited to those who met the
diagnostic criteria for definitive moyamoya disease [22]. As shown
in Table 2, ss179362673 (p.R4810K in RNF213) was significantly
associated with moyamoya disease, with a maximum odds ratio
(OR) of 338.9 (P=10
2100). The association was perfectly
replicated in the Korean (OR=135.6, P=10
226) and Chinese
(OR=14.7, P=10
24) populations (Table 2). Stratification by
family histories of moyamoya disease did not substantially change
the association of p.R4810K with moyamoya disease (Table S9).
Variant searching in non-p.R4810K East Asian cases and
in Caucasian cases
Although p.R4810K was identified in three ethnic populations,
the population attributable risks in the Japanese (145/161; 90%)
and Korean (30/38; 79%) populations were larger than that in the
Chinese population (12/52; 23%). Additionally, we showed by
genotyping that the p.R4810K variant was not present among
Caucasian cases or controls. These pieces of evidence strongly
suggest genetic heterogeneity. We thus sequenced RNF213 to
identify other variants in non-p.R4810K East Asian cases and
Caucasian cases.
By direct sequencing, five distinct RNF213 variants, i.e.,
p.D4863N, p.E4950D, p.A5021V, p.D5160E and p.E5176G,
were identified in seven out of 64 East Asian cases (40 Chinese, 16
Japanese and 8 Korean) (Table 3, Figure S5). None of these
variants was found among 757 East Asian controls (Table 3). In
Caucasians, four distinct variants, i.e., p.N3962D, p.D4013N,
p.R4062Q and p.P4608S, were identified in 4 out of 50 (8%) cases
(Table 3): in the index case of the Caucasian pedigree (Figure S2A)
and 3 out of 49 other cases (Figure S5). In the Czech family, the
p.D4013N (G.A) variant was transmitted to the three affected
children and segregated perfectly with moyamoya disease (Figure
S2). None of these variants was found among 384 Caucasian
controls (Table 3).
In total, our extensive sequencing analysis identified 10 variants
in RNF213 (Table 3). These variants were all located in the 39 half
of the gene (Figure 6). We concluded that RNF213 is a
susceptibility gene for moyamoya disease.
Full-length cDNA cloning of RNF213
Because of its large size, RNF213 was first cloned as five separate
fragments, which were then connected using internal restriction
enzyme sites, as indicated in Figure S6. The 59 and 39 ends of
cDNA from the LCL of the index case of pedigree 11 were
determined by RACE, which defined the transcriptional start site
and the 39 end of the RNF213 gene as at nucleotides 78,234,667
and 78,370,086, respectively (UCSC Genome Browser in
Appendix S1). Thus, the full length RNF213 was found to have
a 15624-bp ORF and 5431-bp 59 and 39UTR. The whole cDNA
of RNF213 [AB537889] is similar in size to the cDNA of RNF213
[NM_020914.4], but there are differences: it lacks exon 4 and has
a3 9UTR 2500 bp longer than that of NM_020914.4 (NCBI in
Appendix S1).
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isolated from bone marrow, cerebellum, whole brain, fetal brain,
fetal liver, heart, kidney, liver, lung, placenta, skeletal muscle,
testis, thymus, spinal cord, artery and HUVECs (Figure 7). The
same splicing variants were also detected in LCLs isolated from the
five controls and the six cases (data not shown). These two isoforms
correspond to the short isoform (270 bp) which skips exon 4
(DDJB, AB537889) and the long isoform (417 bp) which reads
exon 4 (NM_020914.4) (Figure 7). The short isoform is the major
splicing variant and detected in all tissues examined, but the long
isoform is a minor and not found in several tissues.
In silico analysis revealed two well-known domains, a RING
finger domain and a Walker motif, which are reported to exhibit
ubiquitin ligase activity and ATPase activity, respectively (Figure 6)
[31],[32] (Genecard in Appendix S1).
Expression profile of RNF213 and functional
characterization
RNF213 mRNA is expressed in various human tissues
(Figure 8A). Northern blotting revealed the expression of full-
length RNF213 in several human tissues (Figure S7A), cultured cell
lines and LCLs (Figure S7B). We also detected the expression of
the 591-kDa endogenous RNF213 protein in LCLs, HUVECs,
CASMCs and HEK293 cells by western blotting using a RNF213-
specific antibody. The western blot band size was consistent with
that of overexpressed HA-tagged RNF213 (Figure 8B).
Transient transfection of HA-tagged RNF213 into HeLa cells
resulted in expression of the protein throughout the cytosol
(Figure 8C), with partial association with the intracellular
membrane and cytoskeleton (Figure S8B). The E3 activity of
the RING finger domain was confirmed by self-ubiquitination
after transfecting full-length RNF213 cDNA into HEK293 cells
(Figure 8D). ATPase activity was detected in vitro by free phosphate
releasing analysis using a recombinant RNF213 fragment including
the Walker motif (Figure 8E). Thus, RNF213 is a unique protein,
and we report here for the first time that it is a single protein that
possesses both ubiquitin ligase activity and ATPase activity.
Homology search
A homology search revealed conservation of the arginine
residue at position 4810 of RNF213 in mammals (Table 4) (BLAST
in Appendix S1). Three variants: p.R4062Q, which is located in
the RING finger domain, p.R4810K and p.E5176G, were
conserved among most species (Table 4). Variants p.N3962D,
p.P4608S, p.D4863N, p.E4950D, p.A5021V, and p.D5160E were
outside the RING finger domain and not conserved across species
(Table 4). It should be noted that for five variants (p.N3962D,
p.D4013N, p.E4950D, p.A5021V, and p.D5160E), the variant
allele was present at the equivalent position in at least one of the
species examined.
Biochemical effects of p.R4810K and p.D4013N
We tried to characterize the p.R4810K and p.D4013N allele
proteins of RNF213 in vitro. We first investigated stability of the
p.R4810K variant. The wild-type or p.R4810K variant of
RNF213-HA was transiently expressed in HEK293 cells. Cells
were lysed and subjected to immunoblotting with an anti-HA
antibody. As shown, the molecular stability in cells was not altered
(Figure S8A). Next we investigated subcellular localization of the
p.R4810K variant of RNF213. HEK293 cells transiently express-
ing the wild-type or p.R4810K variant of RNF213-HA were
fractionated into cytosol, membrane/organelle, nucleus, and
cytoskeleton using different lysis reagents (ProteoExtract kit;
Calbiochem). However, we could not detect alteration of
intracellular distribution of p.R4810K (Figure S8B). Next we
examined whether self-ubiquitination of the p.R4810K variant or
p.D4013N mutant of RNF213 was altered. HEK293 cells
transiently expressing the wild-type or p.R4810K variant or
p.D4013N mutant of RNF213-HA and Myc-ubiquitin were lysed
and subjected to immunoprecipitation using an anti-HA antibody,
followed by immunoblotting using an anti-Myc antibody. Neither
of the two variants was found to alter ubiquitin activities (Figure
S8C and S8D).
Allele-specific mRNA expression of RNF213
To determine whether RNF213 mRNA from the p.R4810K
(G.A) allele is specifically expressed in moyamoya patients, a
SNaPshot assay was performed (Figure S9). The allele specific
ratios of p.R4810K were between 1.03 and 1.19, suggesting that
there is no allele-specific gene expression in moyamoya patients.
RNF213 orthologues in zebrafish
We could not prove detrimental effects of the variants.
Therefore we aimed to obtain further insight into the physiological
function of RNF213 by suppressing its gene expression in
zebrafish. In zebrafish, two RNF213 genes, RNF213-a and
RNF213-b are located on different chromosomes as a result of
whole-genome duplication. The predicted amino acid sequences
indicate that both RNF213 genes are human RNF213 orthologues
(UCSC Genome Browser in Appendix S1), with nearly perfect
conservation in the Walker and RING finger motifs. These genes
are highly related to one another at the amino acid level, with
RNF213-a and RNF213-b sharing similar exon structures.
However, comparisons of exon-intron boundaries reveal low
conservation in these RNF213 MO target sequences. Therefore we
could design a MO that specifically knocks down each RNF213
gene. Expression analysis by RT-PCR indicated that RNF213-a
was expressed to a greater extent than RNF213-b (Figure S10). In
situ hybridization analysis was not successful, probably because of
weak or scattered expression of each RNF213.
To knock down these RNF213 orthologues, MO nucleotides
were designed to specifically target splice sites (sp-MO). Two pairs
of RNF213-a sp-MO and a RNF213-b sp-MO successfully
interfered with the splicing of RNF213 transcripts (Figure S10).
To assay vascular development, we used the Tg(fli-EGFP)y1 line,
in which endothelial cells are marked by EGFP expression.
Injection of both sp-MO pairs against RNF213-a (pair 1: RNF213-
a-MO1-A and MO1-D, pair 2: RNF213-a-MO2-A and MO2-D)
Figure 4. Transmission patterns of the haplotypes in 42 families. The numbers in the parentheses indicate the haplotypes transmitted in
each family. Haplotype 1 symbolizes non-risk haplotypes collectively. Therefore it comprises various haplotypes. Haplotypes can be seen in Figure 5.
Several family members that were genotyped were omitted in the pedigree chart for clarity. Those members and their haplotypes were; two siblings
(1,1) for pedigree 7; father (1,1) for pedigree 21; father (1,1) for pedigree 22; father (1, 1) and a sibling (1,1) for pedigree 23; father (1,1), mother (2,1)
and a sibling (1,1) for pedigree 26; three siblings (1,1), (1,1) and (1,1) for pedigree 27; father (1,1), three siblings (1,1) (1,1) and (1,1) for pedigree 28;
father (1,1), mother (2,1) and a child of 2 (1,1) for pedigree 32; three siblings (1,1), (1,1), and (1,1) for pedigree 33; mother (1,1) for pedigree 34; father
(1,1) and mother (2,1) for pedigree 36; a sibling (1,1) for pedigree 39; three siblings (1,1), (4,1) and (1,1) for pedigree 40; father (2,1) for pedigree 41;
mother (1,1) for pedigree 42.
doi:10.1371/journal.pone.0022542.g004
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About three quarters of embryos injected with pairs of RNF213-a
morpholinos (2.5 ng each) presented with similar vascular
anomalies by 72 hpf (73% of pair 1, n=177, and 76% of pair
2, n=43). By contrast, injection of a sp-MO against RNF213-b
resulted in normal vascular development, presumably because
little RNF213-b is expressed in vivo (Figure S11).
RNF213 knock-down zebrafish
In bright-field images, RNF213 morphants showed a slight
reduction in body size, a small eye, and a wavy trunk compared to
the control (Figure 9A, left). Formation of the axial trunk vessels,
the dorsal aorta and posterior cardinal vein proceeded almost
normally, indicating that arteriovenous specification was not
affected. Intersegmental vessel sprouts emerged from the dorsal
aorta at regular positions; however, the elongating sprouts did not
track closely to intersegmental boundaries and sometimes reached
dorsal longitudinal anastomotic vessels at the next intersegmental
boundary, although somite boundaries appeared morphologically
normal (Figure 9A, right). These phenotypes were not caused by
general embryonic delay, because the number of somites in
RNF213 morphants and scrambled control morphants were equal.
Severely abnormal sprouting vessels were further seen in the
head region. Large trunk arteries, such as the lateral dorsal aorta,
basilar artery, and primordial channel formed almost normally.
However, these vessels were of an irregular diameter and showed
aberrant sprouting (Figure 9B). Remarkably, RNF213 morphants
sprouted abnormal vessels from the optic vessels at 60-72 hpf. In
control morphants, the inner optic circle (IOC) was formed by a
branch of the nasal ciliary artery; even at later stages, up to 7 days
post-fertilization (dpf), three branches connected the lateral side of
the eyeball to the IOC. However, in two different RNF213
morphants, multiple vessels sprouted from the IOC and connected
to the cranial veins (Figure 9C, red arrow, Figure S11).
Discussion
To identify a causative gene for moyamoya disease, we used
exome analysis in eight index cases who met the RCMJ criteria
and whose families comprised three generations of patients. Thus,
our cases and families can safely be assumed to be prototypical for
familial moyamoya disease. For filtering we employed a modified
version of Ng et al.’s criteria [29]. This modification was made to
take account of the possible involvement of uncharacterized genes
Figure 5. Risk haplotypes transmitted in 42 families. The orange regions represent the haplotype of the index case of pedigree 11. The yellow
regions indicate rare variants. The red and white regions represent flanking SNPs and SNPs outside of the founder haplotype, respectively. The
minimum founder haplotype fell in a a region in a span of 130 kb covering RNF213 and FLJ35220. The physical positions were referred from Build
37.1.
doi:10.1371/journal.pone.0022542.g005
Table 2. Association of ss179362673 with moyamoya disease.
Ethnicity HWE P Cases HWEPControls DD Cases DDControls DdCases Dd Controls dd Cases dd Controls Sample Size
Japanese 0.00 0.00 10 1 135 9 16 374 545
Korean 0.00 0.84 0 0 30 6 8 217 261
Chinese 0.81 0.92 1 0 11 2 40 98 152
Total 0.00 0.01 11 1 176 17 64 689 958
Model Ethnicity Chi-Squared
(-log10P)
OR (Minor
Allele)
Lower CI Upper CI Minor Allele
Frequency
(Cases)
Minor Allele
Frequency
(Controls)
Allelic Japanese 84.63 63.87 33.88 120.42 0.48 0.01
Korean 33.11 47.83 18.91 120.93 0.40 0.01
Chinese 4.95 14.14 3.13 63.98 0.13 0.01
Total 117.73 47.82 29.39 77.81 0.39 0.01
Additive Japanese 100.20 244.58 113.98 525.32
Korean 26.12 135.63 43.03 427.52
Chinese 4.64 13.69 2.86 65.56
Total 117.66 97.11 56.15 168.01
Dominant Japanese 99.98 338.94 147.82 777.44
Korean 26.12 135.63 43.03 427.52
Chinese 4.58 14.70 3.05 70.81
Total 119.18 111.84 64.01 195.39
Recessive Japanese 4.84 25.36 3.09 208.30
Korean 0.92 0.36 0.08 1.61
Chinese 0.10 0.88 0.33 2.36
Total 5.91 32.36 3.99 262.70
OR: odds ratio; CI: 95% Confidence Interval; HWE: Hardy Weinberg Equilibrium; DD: minor allele homozygote; Dd: heterozygote; dd: major allele homozygote;
SE: Standard error.
doi:10.1371/journal.pone.0022542.t002
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obtained two candidate genes, PCMTD1 and RNF213. The former
was discarded because it was not replicated by Sanger method in
any of the eight index cases. However, p.R4810K in the latter
showed complete disease segregation in all 42 families, confirming
the previously identified genetic locus 17q25.3 [19]–[21].
Table 3. Summary of the variants in RNF213.
Variant 78358945 78360097 78360619 78363034 78367154 78367201 78341560 78341825 78343331 78355371 Total
G.AG .AG .CC .TC .GA .GA .GG .AG .AC .T
Effect* p.R4810K p.D4863N p.E4950D p.A5021V p.D5160E p.E5176G p.N3962D p.D4013N p.R4062Q p.P4608S
Japanese Case
(n=161)
1 4 5 ( 1 0 ) 0000000001 4 5
M A F 4 8 . 1 0000000004 8 . 1
Control
(n=384)
1 0 ( 1 ) 0 0 0 0 0 N DN DN DN D1 0
MAF 1.4 0 0 0 0 0 ND ND ND ND 1.4
Korean Case
(n=38)
3 0 ( 0 ) 0000000003 0
M A F 3 9 . 5 0000000003 9 . 5
Control
(n=223)
6 ( 0 ) 0 0 0 0 0 N DN DN DN D6
MAF 1.3 0 0 0 0 0 ND ND ND ND 1.3
Chinese Case
(n=52)
1 2 ( 1 ) 1221100001 9
MAF 12.5 1 1.9 1.9 1 1 0 0 0 0 19.3
Control
(n=150)
2 ( 0 ) 0 0 0 0 0 N DN DN DN D2
MAF 0.7 0 0 0 0 0 ND ND ND ND 0.7
Total in
East Asian
Case
(n=251)
1 8 7 1221100001 9 4
% 74.5 0.4 0.8 0.8 0.4 0.4 0 0 0 0 77.3
Control
(n=757)
1 8 0 0 0 0 0 N DN DN DN D1 8
% 2.4 0.0 0.0 0.0 0.0 0.0 ND ND ND ND 2.4
Czech Case
(n=8)
00000001001
M A F 00000006 . 3 006 . 3
Control
(n=120)
0 N DN DN DN DN D0 0 0 0 0
M A F 0 N DN DN DN DN D0 0 0 0 0
German Case
(n=42)
00000010113
MAF 0 0 0 0 0 0 1.2 0 1.2 1.2 3.6
Control
(n=164)
0 N DN DN DN DN D0 0 0 0 0
M A F 0 N DN DN DN DN D0 0 0 0 0
Caucasian Control
(n=100)
0 N DN DN DN DN D0 0 0 0 0
M A F 0 N DN DN DN DN D0 0 0 0 0
Total in
Caucasian
Case
(n=50)
00000011114
% 00000022228
Control
(n=384)
0 N DN DN DN DN D0 0 0 0 0
% 0 ND ND ND ND ND 0 0 0 0 0
*Based on AB537889.
ND: Not determined.
() :Number of homozygotes.
MAF: Minor allele frequency.
doi:10.1371/journal.pone.0022542.t003
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with moyamoya disease (OR=111.8) in all East Asian cases.
Finally, we searched for variants in RNF213 in non-p.R4810K
East Asian cases and in Caucasian cases. We found five novel
variants in seven Chinese cases and four variants in four
Caucasian cases.
Additionally, we identified a founder haplotype and its decayed
haplotypes in 42 families. Homogeneity of the haplotypes was
confirmed by genotyping of 39 SNPs. These observations strongly
suggest that the causative variant should be located within the core
LD block region spanning from RNF213 to NPTX1. However,
complete sequencing of this region including promoter, intron and
intergenic regions in one of the index cases did not show any
variants other than p.R4810K or a G.A substitution in intron 11
of FLJ35220. The latter variant did not have any effect on splicing
or gene expression levels. Furthermore we failed to detect any
small Indel in exons in the eight index cases and large CNVs in
three index cases in 17q25.3, although we missed small intronic
structural abnormalities, which might be a possible cause of
moyamoya disease. Taken together, these lines of evidence
consistently support a conclusion that RNF213 is a susceptibility
gene for moyamoya disease. Recently a significant association of a
SNP in RNF213 with moyamoya disease in Japanese has been
shown [33].
As we previously reported, the penetrance of autosomal
dominant moyamoya disease is low, as illustrated by discordant
identical twins or ‘‘skipping a generation’’ [34]. This characteristic
of moyamoya disease is in accordance with the notion that
RNF213 is a susceptibility gene for moyamoya disease and
reconciles our unexpected observation that this variant was found
at an allele frequency of 1% in the Japanese, Korean and Chinese
control populations. In addition, the low identification rates of
RNF213 variants in Caucasians compared with East Asians
strongly suggests that there is genetic heterogeneity of moyamoya
disease between these two populations. In addition, there are
obvious differences in the variants themselves between East Asians
and Caucasians. Further studies are needed to investigate whether
such allelic differences result in the different clinical features.
By cloning the cDNA for this region, we discovered a novel
splicing variant for RNF213 (AB537889), which lacks exon 4 of
RNF213 [NM_020914.4]. This new splicing variant of RNF213 is
a major transcript of RNF213. We have experimentally proven
that two functional domains, a Walker motif and a RING finger
domain, function. Such novel features of RNF213 hampered our
elucidation of its physiological function.
To characterize the physiological role of RNF213 in vivo,w e
investigated the effects of RNF213 suppression on zebrafish
vasculature. RNF213 knockdown zebrafish showed severely
abnormal sprouting vessels in the head region, especially from
the optic vessels at 60–72 hpf. In normal embryos, the overall
wiring pattern of the major vessels is largely completed by 2–
2.5 dpf, despite massive development of smaller-caliber vessels in
the head through to 7 dpf [35]. Therefore, the aberrant vessel
formation from the IOC seen in RNF213 morphants at this stage
implies a severely impaired program of angiogenesis in the head
region. Although abnormal vascular phenotypes in the tail region
have been reported after manipulation of genes such as plexin D1
[36], morphants showing aberrant vascular sprouting from the
IOC have never been seen [37], suggesting that RNF213 is
involved in a novel signaling pathway in intracranial angiogenesis.
As such, we expect that once we identify the pathway, we may be
able to elucidate the consequences of vascular remodeling in
moyamoya disease [9], [12], [23], [38]. We are aware of a
limitation in the current study as a morpholino rescue experiment
was not conducted. The rescue experiment is technically difficult
to achieve because of the extremely large size of the RNF213
Figure 6. Genomic structure, domains of RNF213 and variants. Genomic structure was based on DDBJ/EMBL-Bank/GenBank accession
number AB537889. Domain structure was obtained by GeneCards.
doi:10.1371/journal.pone.0022542.g006
Figure 7. Two isoforms of alternative splicing variants of
RNF213. We have tested whether exon 4 is read through or not in cDNA
isolated from various human tissues and HUVECs. Representative results
of human tissue RNAs and HUVEC are shown. A short isoform, which
skips the exon 4, has an expected size of 270 bp (AB537889) and a long,
which reads exon 4, has an expected size of 417 bp (NM_020914.4).
doi:10.1371/journal.pone.0022542.g007
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phenotypes shown by two different RNF213 morphants indicate
that these phenotypes were derived from the specific deletion of
RNF213 and not from an off-target effect of a morpholino.
A question remains as to how the p.R4810K variant or other
nine variants may impair the physiological function of RNF213
thereby resulting in moyamoya disease. We could not demonstrate
that p.R4810K or p.D4013N affects ubiquitin ligase activity or
causes other hallmark changes such as mRNA or protein
instability. Furthermore, it appears that there was no gene dosage
effect because some Japanese controls were homozygous (Table 2).
In addition, homology search argued against pathological roles for
some variants. It is thus probable that these variants likely perturb
RNF213 function by unidentified mechanisms other than through
ubiquitin ligase activity or by decreasing protein stability or by
mislocalization. At present, we cannot specify the mechanism as
haploinsufficiency, dominant negative or gain of function; instead
we postulate the involvement of another factor. Requirement of
co-factors with RNF213 might also explain the lower disease
prevalence (1 in 10,000) than expected from the relatively high
minor allele frequency of approximately 1%. Furthermore, despite
similar frequencies of p.R4810K, population attributable risks
were different among the three East Asian populations, suggesting
existence of environmental factors or another genetic factor. It
should be noted, however, that involvement of the additional
genetic factor is unlikely because the gene, RNF213, was singularly
filtered as the common genetic factor by exome. We consider it
rational to postulate involvement of environmental factors rather
than genetic factors. Several environmental factors may include
autoimmune conditions [39], [40], infection [41]–[45] and
exposure to radiation [46]. Recently, Bauersachs et al. reported
that RNF213 is upregulated in bovine endometrium by pregnancy
[47]. In addition, Zhang et al. reported that intracellular parasites
and cytokines upregulate RNF213 [48]. These findings support
that RNF213 is upregulated by inflammatory signals generated by
interferon or cytokines. Of particular interest is transforming
growth factor beta (TGF-b), because it is known to be elevated in
the cerebrospinal fluid, blood and arteries of patients with
moyamoya disease [23], [38] and a SNP within TGF-b has been
reported to be associated with moyamoya disease [49]. Further
study on cross-talk of RNF213 with such conditions that cause
endothelial damage, or angiogenesis factors is needed to
understand the molecular mechanisms.
Sharing p.R4810K among moyamoya cases urged us to discuss
the anthropological history of the founder haplotype carrying
p.R4810K. p.R4810K appears to be a neutral variant or an
advantageous variant for human survival because it has been
maintained in the East Asian population. It is interesting that
Figure 8. Characterization of the RNF213 gene and protein. (A) RNF213 mRNA expression. Total RNA from the indicated human tissues was
reverse-transcribed to cDNA, and real-time quantitative PCR was performed. (B) RNF213 protein expression. LCL, HUVEC, and CASMC were lysed and
immunoblotted using an anti-RNF213 antibody. HEK293 cells transiently expressing RNF213-HA (+) or control cells (2) were immunoblotted using
anti-RNF213 and anti-HA antibodies. (C) Subcellular localization of RNF213. HeLa cells transiently expressing RNF213-HA were stained with an anti-HA
antibody. (D) Self-ubiquitination of RNF213. HEK293 cells transiently expressing RNF213-HA and Myc-ubiquitin (Myc-ub) were lysed and subjected to
immunoprecipitation (IP) using an anti-HA antibody, followed by immunoblotting (IB) using an anti-Myc antibody. As a control, immunoblotting was
also performed with an anti-HA antibody. (E) ATPase activity of RNF213. Free phosphate released from ATP by the ATPase activity of a recombinant
RNF213 fragment (a.a. 2359–2613) tagged with GST was measured using the Malachite Green method. a.a., amino acid. IP, immunoprecipitation. IB,
immunoblot.
doi:10.1371/journal.pone.0022542.g008
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PLoS ONE | www.plosone.org 16 July 2011 | Volume 6 | Issue 7 | e22542p.R4810K was not found in Caucasians; the relatively high
prevalence of p.R4810K among East Asians could account for the
higher prevalence of moyamoya disease in East Asians than in
Caucasians.
This study has several limitations. First, we cannot provide
evidence regarding impairment of physiological function of these
variants of RNF213 in moyamoya disease. Second, the number of
subjects used for deep sequencing or CNVs was small. The
strengths of our study are that we conducted whole genome-exome
analysis and demonstrated strong evidence showing involvement
of a single gene, RFN213, in moyamoya disease. Other strengths
include that we found a founder variant in East Asian cases, an
additional nine variants in Chinese and Caucasian cases, and
characterized the RNF213 protein biochemically and physiolog-
ically. Although further studies are necessary to clarify the
biochemical function and pathological role of RNF213 in
moyamoya disease, the discoveries of its association with the
disease and its unique roles in angiogenesis may pave a way to
early diagnosis and prevention. It should be noted, however, that
the majority of the pathological proof awaits further studies.
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Text S1 Supplemental methods, reference and acknowledg-
ments.
(DOC)
Appendix S1 Web Resources.
(DOC)
Figure S1 Pedigree chart. Forty-one Japanese families and one
Korean (pedigree 40) family participated in this study. The
phenotypes of occlusive lesions are shown. Genotype of p.R4810K
(G.A) is shown in brackets.
(TIF)
Figure S2 A variant in a Caucasian family. The index case is the
father (CAU_ped1_12), who was born in 1966 and suffered a mild
ischemic stroke at the age of 30. His mother died of an ischemic
stroke at the age of 35. He has four children from two marriages.
The second child from the first marriage (CAU_Ped1_122) was
born in 1991 and developed moyamoya disease at the age of 5.
The first child of the second marriage (CAU_Ped1_123) was born
in 1999 and developed moyamoya disease with symptoms of
involuntary movement at the age of 9. The second child,
(CAU_Ped1_124) born in 2006, developed moyamoya disease
with manifestations of ischemic stroke at the age of 3. Diagnoses of
moyamoya disease were made by magnetic resonance imaging
(MRI). (A) Caucasian pedigree. The index case (father) and his
three affected children carry the p.D4013N variant of RNF213
(G.A). Genotypes of the variant for each member are shown in
the bracket in the pedigree. (B) Sequencing analysis. (C)
Genotyping by HpyCH4V.
(TIF)
Figure S3 Effect of G.A substitution in intron 11 of FLJ35220
on splicing or gene expression. (A) We tested whether exon 11 was
read through. A short form, which skips exon 11, had an expected
size of 107 bp. A long form, which reads through exon 11, had an
expected size of 166 bp (NM_173627.2). M, 100 bp ladder DNA
marker. (B) FLJ35220 mRNA expression in LCLs [controls; JPN1,
an unaffected daughter (Ped17_123) of Ped17_12 and an
unaffected spouse (Ped18_20) of Ped18_2; cases: Ped11_11,
Ped17_12, Ped18_2 and Ped18_22] as determined by real-time
quantitative PCR. Data are shown as means 6 S.D. of three
independent experiments. There is no statistically significant
difference between the two groups. Significance was tested using
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methods have been fully described in the Text S1.
(TIF)
Figure S4 Copy number analysis for the 1.5-Mb region in
17q25.3. Three index cases of pedigrees 5, 11 and 18 were
analyzed. The blue lines represent the copy numbers (log 2 ratio)
averaged over 10 SNPs. The copy numbers were compared with
control spouse of 2 of pedigree 18.
(TIF)
Figure S5 Sequence chromatograms for the eight novel variants.
(TIF)
Figure S6 Cloning of full-length RNF213 cDNA. Schematic
representation of the internal connecting site of RNF213 cDNA.
RT-PCR with primers set on RNF213 resulted in amplification of
the expected fragments. First, fragments 1, 2, 4, and 5 were cloned
into a pcDNA3.1+ vector. Second, fragment 3 was cloned into the
vector carrying fragment 2, and fragment 5 was subcloned into the
vector carrying fragment 4. Then fragments 2–3 and 4–5 were
subcloned into fragment 1 using the restriction enzyme sites
indicated.
(TIF)
Figure S7 Northern blotting analysis of RNF213 mRNA. (A)
RNF213 mRNA expression in the indicated human tissues (heart,
brain, liver, pancreas, skeletal muscle, and lung). Arrow indicates
RNF213 mRNA. (B) RNF213 mRNA expression in cultured
human cells (HeLa, HEK293T and LCLs (control: JPN1,
Ped18_20 (a spouse of 2) and case: Ped18_2, Ped18_22,
Figure 9. Depletion of RNF213 causes abnormal vessel sprouting in zebrafish. Tg(fli-EGFP)y1 embryos at 72 h post-fertilization. (A)
Brightfield image of whole embryos (left) and confocal images of tail vessels (right) of embryos injected with a control (scrambled) or RNF213
morpholino (MO). Lateral views, dorsal uppermost, anterior to the left. In RNF213 morphants, abnormal intersegmental vessel sprouting was observed
(white arrowheads). Trunk vessels, including the dorsal aorta (red arrowheads), posterior cardinal vein (blue arrowheads) and dorsal longitudinal
anastomotic vessels (yellow arrowheads) developed almost normally. (B) Confocal images of intracranial vessels. (Left) Lateral views 20 degrees
toward the top; dorsal uppermost, anterior to the left. (Right) Dorsal views, head to the left. The trunk artery, including the basilar artery (red arrows),
lateral dorsal aorta (blue arrows), mesencephalic artery (yellow arrows) and dorsal longitudinal vein (white arrowheads) developed almost normally in
controls and RNF213 morphants. RNF213 morphants showed abnormal sprouting vessels (yellow arrowheads) and irregular vessel diameter (white
arrowheads). (C) Cross-sectional view at the middle of the lens level. In a control morphant, the three branches of the nasal ciliary artery (red
arrowheads) drain into the inner optic circle (IOC; blue arrowheads). In two different RNF213 morphants, multiple aberrant vessels drain into the IOC
(red arrowheads), and occasionally part of the IOC was missing (yellow arrowhead).
doi:10.1371/journal.pone.0022542.g009
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PLoS ONE | www.plosone.org 18 July 2011 | Volume 6 | Issue 7 | e22542Ped11_11)) using radiolabelled probes corresponding to RNF213
coding regions. GAPDH mRNA expression is shown as a loading
control. The position of RNA Millennium markers (Ambion) and
positions of the 18S and 28S ribosomal RNAs are indicated on
the left.
(TIF)
Figure S8 Characterization of the p.R4810K and p.D4013N
allele proteins of RNF213. (A) Stability of the p.R4810K variant.
Wild-type or p.R4810K variant of RNF213-HA were transiently
expressed in HEK293 cells. Cells were lysed and subjected to
immunoblotting with an anti-HA antibody. IP, immunoprecip-
itation. IB, immunoblot. (B) Subcellular localization of the
p.R4810K variant of RNF213. HEK293 cells transiently
expressing the wild-type or p.R4810K variant of RNF213-HA
were fractionated into cytosol, membrane/organelle, nucleus,
and cytoskeleton using different lysis reagents (ProteoExtract kit,
Calbiochem). (C) Self-ubiquitination of the p.R4810K variant of
RNF213. HEK293 cells transiently expressing the wild-type or
R4810K variant of RNF213-HA and Myc-ubiquitin were lysed
and subjected to immunoprecipitation using an anti-HA
antibody, followed by immunoblotting using an anti-Myc
antibody. (D) Self-ubiquitination of the p.D4013N mutant of
RNF213. HEK293 cells transiently expressing the wild-type or
p.D4013N mutant of RNF213-Flag and Myc-ubiquitin were
lysed and subjected to immunoprecipitation using an anti-Flag
antibody, followed by immunoblotting using an anti-Myc
antibody.
(TIF)
Figure S9 Allele-specific mRNA expression of RNF213 by
labeling and detection of the two alleles of marker SNPs
p.R4810K and p.H4557H. (A) Design of allele-specific mRNA
expression using SNaPshot assay. Arrows indicate primer positions
for amplification. Bold arrows indicate extension primers for each
SNP. (B) Genotypes of RNF213 gene at two SNPs (p.H4557H and
p.R4810K) in cases for SNaPshot assay. (C) Allele-specific ratio of
RNF213 mRNA expression in LCLs from SNP heterozygous
patients. The common allele/rare allele ratio from cDNA was
normalized to that ratio from genomic DNA of the same
individual. Data are shown as means 6 S.D. of three independent
experiments. There was no statistically significant difference
between the two alleles for each SNP. Significance was tested by
Student’s t-test. A p,0.05 was considered to be significant.
(TIF)
Figure S10 Splicing ablation of RNF213 transcripts by
morpholino injection. RT-PCR showing the defective splicing
induced by RNF213-a-MO1 and MO2 pairs and a RNF213-b-
MO. Compared with the results of PCR (using primer pairs
RNF213-a_2 and 2R, RNF213-b_3 and 3R, and RNF213-b_1
and 1R) from noninjected embryos, where a single band was
generated (lanes 1, 3, and 5, marked ‘‘native’’), split bands were
detected in PCR using embryos injected with a RNF213-a-MO1,
MO2 pair and a RNF213-b-MO (lanes 2, 4, and 6, marked ‘‘exon
blocked’’). M, 1-kb ladder DNA marker. Band indicated by
‘genomic’ is the amplified genomic sequence. Equal amounts of
PCR products and marker were loaded in each lane. Intensity of
RT-PCR products indicates that RNF213-a is dominantly
expressed in vivo.
(TIF)
Figure S11 RNF213 morphants show multiple sprouting vessels
from IOC. Bar graphs showing the number of sprouting vessels
from IOC of Tg(fli-EGFP)y1 embryos 72 h post-fertilization. Each
group was injected with 2.5 ng morpholinos (MO1, MO2) per
embryo indicated in each lane. n=20 per group. Values are means
6 SD. *p,0.01 versus control scramble morphants. #p,0.01
versus RNF213-b-morphants. Neither group of controls nor
RNF213-b showed any extra sprouting vessels.
(TIF)
Table S1 Demographic feature of familial participants.
(XLS)
Table S2 Summary of demographic and clinical profiles of cases
and controls.
(XLS)
Table S3 Primers used for amplification of RNF213 and
PCMTD1 (Human build 37.1).
(XLS)
Table S4 Positional candidate genes in the 1.5 Mb locus on
17q25.3 (Map Viewer: Build 37.1).
(XLS)
Table S5 Primer sets and restriction enzymes for screening
variants in controls.
(XLS)
Table S6 Primers used for SNaPshot assay.
(XLS)
Table S7 Numbers of variants and candidate genes in the 2nd
stage for various combination subsets of cases.
(XLS)
Table S8 A summary of the sequencing results for five controls
by exome, 10 controls and deep sequencing in a control by the
Sanger method.
(XLS)
Table S9 Association of ss179362673 with moyamoya disease
with or without family histories by allelic model.
(XLS)
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